Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors

Objective: To establish whether LPA determination improves the differentiation of benign from malignant ovarian tumors.

Methods: Total LPA and LPA species in the serum were determined using a novel method in 142 patients with ultrasound (US) suspecious ovarian tumors and in 78 healthy women. All women underwent determination of CA125 in the serum, a vaginal US examination and morphology scoring of the tumor.

Results: The levels of total LPA and its species in women with ovarian tumors were significantly higher from those in healthy women (p < 0.001). No significant difference was found in the levels of total LPA or any of its species between the women with benign and those with malignant ovarian tumors.

Conclusions: Determination of serum LPA would be an appropriate test for ovarian tumor presence, especially in women of reproductive age. The method however does not differentiate benign from malignant ovarian tumors.

Lysophosphatidic acid; Benign and malignant ovarian tumors; Predictive value

[1] NIH Consensus Development Panel on Ovarian Cancer. NIH consensus conference: "Ovarian cancer. Screening, treatment and follow-up". J. Am. Med. Assoc., 1995, 273, 6, 491.

[2] Adams Hillard P.J.: "Benign diseases of the female reproductive tract: symptoms and signs". In: Berek J.S. (ed.): "Novak's Gynecology", Philadelphia, Lippincott Williams & Wilkins, 2002, 351.

[3] Berek J.S.: "Epithelial ovarian cancer". In: Berek J.S., Hacker N.F. (eds.): "Practical Gynecologic Oncology". Ph山delphia,Lippincot Williams&Wilkins, 2005, 43.

[4] Valentin L.: "Use of morphology to characterize and manage common adnexal masses". Best Pract. Res. Clin. Obstet. Gynaecol., 2004, 18, 1, 71.

[5] Ferrazzi E., Zanetta G., Dordoni D., Berlanda N., Mezzopane R., Lissoni A.A.:'Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study". Ultrasound Obstet. Gynecol., 1997, 10, 3, 192.

[6] Ueland F.R., DePriest P.O., Pavlik E.J., Kryscio R.J., van Nagell J.R. Jr.: "Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography". Gynecol. Oneal., 2003, 91, 1, 46.

[7] Marchetti M., Zambon A., Lamaina V., Spadaro M.. Marchiori S.: "Ultrasound as a possible screening method in ovarian cancer". Eur. J. Gynaecol. Oneal., 2002, 23, 2, 123.

[8] Petricoin E.F., Ardekani A.M., Hitt B.A. et al.: "Use of proteom1c patterns in serum to identify ovarian cancer". Lancet, 2002, 359, 9306, 572.

[9] Xu Y., Shen Z., Wiper D.W. et al.: "Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers'. JAMA, 1998, 280, 8, 719.

[10] Moolenaar W.H.: "Developement of our current understanding of bioactive lysophospholips“ Ann. N. Y Acad. Sci., 2000. 905, 1.

[11] Aoki J.: "Mechanisms of lysophosphatidic acid production" Semin. Cell. Dev. Biol., 2004, 15, S, 477.

[12] Baker D.L., Desiderio D.M., Miller D.D., Tolley B., Tigyi GJ.: 'Dirrect quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry". Anal. Biochem., 200 I. 292, 2,287.

[13] Sugiura T., Nakane S., Kishimoto S., Waku K., Yoshioka Y., Tokumura A.: "Lysophosphatidic acid, a growth factor-like lipid, in the saliva". J. Lipid. Res., 2002, 43, 12, 2049.

[14] Tokumura A.. Miyake M., Nishioka Y., Yamano S., Aono T., Fukuzawa K.: "Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of In vitro fert山zation patients". Biol. Reprod., 1999, 61, 1, 195.

[15] Xu Y., Gaudette D.C.. Boynton J.D. et al.: "Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients". Clin. Cancer. Res., 1995, 1, 10.1223.

[16] Sutphen R., Xu Y., Wilbanks G.D. et al.: "Lysophospholipids are potential biomarkers of ovarian cancer". Cancer Epidemiol. Biomarkers Prev., 2004, 13, 7. 1185.

[17] Lerner J.P., Tirnor-Tritsch I.E., Federman A., Abramovich G "Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system''. Am. J. Obstet. Gynecol., 1994, 170, 1, 81.

[18] Sassone AM.. Timor-Tritsch I.E., Artner A., Westhoff C., Warren W.B.: "Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy". Obstet. Gynecol., 1991, 78, I, 70.

[19] Meleh M., Pozlep B., Mlakar A., Meden-Vrtovec H., Kralj-Zupancic L.:" Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer". J. Chromlogr. B. (submitted).

[20] Shen Z., Wu M., Elson P. et al.: "Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases". Gynecol. Oneal., 2001, 83, 1, 25.

[21] Kim H.,H ye-Ran Y ,P yod D.:" Quantitative analysis of lysophosphat dic acid in human plasma by tandem mass spectrometry'' Bull. Corean. Chem. Soc., 2002, 23, 8, 1139.

[22] Baker D.L.. Morrison P., Miller B. et al.: "Plasma lysophospha tidic acid concentration and ovarian cancer". JAMA, 2002,2 87, 23, 3081.

[23] Croset M., Brossard N., Polette A., Lagarde M.: ·'Characterization of plasma unsaturated lysophosphatidylcholines in human and rat". Biochem. J., 2000, 345 Pt 1, 61.

[24] Erickson J.R., Hasegawa Y., Fang X. et al.:''Lysophosphatid1c acid and ovarian cancer: a paradigm for tumorogenesis and patient management". Prostaglandins, 2001, 64, 1. 63.

[25] Fritsche H.A.. Bast R.C.: "CA 125 in ovarian cancer: advances and controversy". Clin. Chem., 1998, 44, 7, 1379.

[26] Rosen D.G., Wang L., Atkinson J.N. et al.: "Potential markers that complement expression of CAl 25 in epithelial ovarian cancer". Gynecol. Oneal., 2005, 99, 2, 267.

[27] van Nagell J.R., DePriest P.D.: "Management of adnexal masses in postmenopausal women". Am. J. Obstet. Gynecol., 2005, 193, 1, 30.

[28] Granberg S., Norstrom A., Wikland M.: "Tumors in the lower pelvis as imaged by vaginal sonography". Gynecol. Oneal., 1990, 37, 2, 224.